IL-6 Prevents Lung Macrophage Death and Lung Inflammation Injury by Inhibiting GSDME- and GSDMD-Mediated Pyroptosis

Xuemei Gou1,2, Wenchun Xu1, Yusi Liu3

  • 1Key Laboratory of Diagnostic Medicine Designated by the Ministry of Education, Chongqing Medical University, Chongqing, China.

Microbiology Spectrum
|March 17, 2022
PubMed

Insights

Interleukin-6 (IL-6) protects against pneumococcal pneumosepsis by preventing lung macrophage death and inflammation. This discovery offers a new therapeutic target for this severe bacterial infection.

Area of Science:

  • Immunology and Infectious Diseases
  • Cellular Biology and Inflammation

Background:

  • Streptococcus pneumoniae causes severe infections, including pneumococcal pneumosepsis, leading to high mortality, especially in antibiotic-resistant cases.
  • The mechanisms driving pneumosepsis development and outcomes, particularly unresolved inflammation, remain unclear.
  • Interleukin-6 (IL-6) is crucial for immune homeostasis but its role in pneumosepsis was not fully understood.

Purpose of the Study:

  • To investigate the role of IL-6 in resisting pneumococcal pneumosepsis and its impact on macrophage pyroptosis and lung inflammation.
  • To elucidate the protective mechanisms of IL-6 against Streptococcus pneumoniae-induced lung injury.

Main Methods:

  • Utilized a mouse model of Streptococcus pneumoniae infection to assess IL-6's influence on infection outcomes.
  • Examined the effects of IL-6 deficiency and exogenous IL-6 administration on lung macrophage death and inflammation.
  • Investigated IL-6's inhibition of gasdermin E (GSDME)- and gasdermin D (GSDMD)-mediated pyroptosis in macrophages.

Main Results:

  • IL-6 demonstrated a critical protective role against pneumosepsis, primarily by acting on macrophages.
  • IL-6 deficiency resulted in increased lung macrophage death and exacerbated lung inflammation.
  • Exogenous IL-6 administration reduced macrophage death and alleviated lung inflammation, inhibiting GSDME- and GSDMD-mediated pyroptosis.

Conclusions:

  • IL-6 is essential for resisting pneumococcal pneumosepsis by inhibiting macrophage pyroptosis and subsequent lung inflammation.
  • This study reveals a novel mechanism for pneumosepsis development and highlights IL-6's protective function.
  • Findings support IL-6 as a potential therapeutic target for early identification and treatment of pneumococcal pneumosepsis.